CN Patent

CN121909205A — 作为选择性il-23受体抑制剂的新型肽

Assigned to Sanofi Aventis France · Expires 2026-04-21 · 0y expired

What this patent protects

本披露涉及式(I)的IL‑23受体抑制剂化合物、其药物组合物及其医学用途，例如在治疗克罗恩病等炎性肠病中的医学用途。

USPTO Abstract

本披露涉及式(I)的IL‑23受体抑制剂化合物、其药物组合物及其医学用途，例如在治疗克罗恩病等炎性肠病中的医学用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN121909205A
Jurisdiction: CN
Classification: —
Expires: 2026-04-21
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Aventis France
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.